Slate Medicines Funding: $130M Raised, Series A (2025)
Slate Medicines is a Biotech company based in Raleigh, North Carolina. It has raised $130M in total funding. Latest round: Series A.
Slate Medicines funding overview
Slate Medicines is a Biotech company based in Raleigh, North Carolina. Slate Medicines has raised $130M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in February 2025. The round record for Slate Medicines runs through 2025; nothing later has been disclosed. Investors on record include RA Capital Management, Forbion, Foresite Capital. 3 distinct backers are named across the disclosed rounds.
Slate Medicines at a glance
Total raised
$130M
Latest round
Series A
Latest round date
February 2025
Industry
Biotech
Headquarters
Raleigh, North Carolina
Notable investors
RA Capital Management, Forbion, Foresite Capital
Frequently asked about Slate Medicines funding
How much has Slate Medicines raised?
Slate Medicines has raised $130M in total disclosed funding across the rounds on record.
Who has invested in Slate Medicines?
RA Capital Management, Forbion, Foresite Capital are named among the investors backing Slate Medicines.
What was the latest Slate Medicines funding round?
The most recent disclosed round is a Series A, announced in February 2025.
Where is Slate Medicines based?
Slate Medicines is based in Raleigh, North Carolina.
What sector does Slate Medicines operate in?
Slate Medicines is tracked under Biotech from Raleigh, North Carolina, with $130M in disclosed funding.
When did Slate Medicines last raise?
The last disclosed Slate Medicines round closed in February 2025 at Series A.
We update the Slate Medicines record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related Biotech companies in Raleigh and their backers are listed below.
